Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07839369.1Aexternal-prioritypatent/EP2084174B1/en
Application filed by Gilead Pharmasset LlcfiledCriticalGilead Pharmasset Llc
Publication of CY1114666T1publicationCriticalpatent/CY1114666T1/en
Η παρούσα διεργασία παρέχει μια βελτιωμένη μέθοδο για την παρασκευή της 4-αμινο- 1-((2R,3R,4R,5R)-3-φθορο-4-υδροξυ-5-υδροξυμεθυλ-3-μεθυλ-τετραϋδρο-φουραν-2-υλ)-1Η-πυριμιδιν-2-όνης του τύπου (IV) η οποία είναι ένας ισχυρός αναστολέας της πολυμεράσης ΝS5B του Ιού της Ηπατίτιδας C (ΗCV).The present process provides an improved method for the preparation of 4-amino-1- ((2R, 3R, 4R, 5R) -3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2- yl) -1H-pyrimidin-2-one of formula (IV) which is a potent inhibitor of hepatitis C virus NS5B polymerase (HCV).
CY20131100912T2006-10-102013-10-16
PREPARATION OF NUCLEOSIDE RIBOFURANOSYL PYRIMIDINES
CY1114666T1
(en)
Isopropyl ester of the acid (s) -2 - {[(2r, 3r, 4r, 5r) -5- (2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl) -4-fluoro- 3-hydroxy-4-methyl-tetrahydro-furan-2-yl-methoxy] -phenoxy-phosphorylamino} -propionic; preparation process, pharmaceutical composition and its use to treat hepatitis c, west nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus.
Compounds derived from cyclopropyl uracil nucleotides, hepatitis c virus polymerase inhibitors; pharmaceutical compositions; and use of the compound for the treatment of hepatitis c (hcv).